Maekawa Keiko, Saeki Mayumi, Saito Yoshiro, Ozawa Shogo, Kurose Kouichi, Kaniwa Nahoko, Kawamoto Manabu, Kamatani Naoyuki, Kato Ken, Hamaguchi Tetsuya, Yamada Yasuhide, Shirao Kuniaki, Shimada Yasuhiro, Muto Manabu, Doi Toshihiko, Ohtsu Atsushi, Yoshida Teruhiko, Matsumura Yasuhiro, Saijo Nagahiro, Sawada Jun-Ichi
Division of Biochemistry and Immunochemistry, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo, 158-8501, Japan.
Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan.
J Hum Genet. 2007;52(10):804-819. doi: 10.1007/s10038-007-0186-6. Epub 2007 Sep 9.
Dihydropyrimidine dehydrogenase (DPD) is an inactivating and rate-limiting enzyme for 5-fluorouracil (5-FU), and its deficiency is associated with a risk for developing a severe or fatal toxicity to 5-FU. In this study, to search for genetic variations of DPYD encoding DPD in Japanese, the putative promoter region, all exons, and flanking introns of DPYD were sequenced from 341 subjects including cancer patients treated with 5-FU. Fifty-five genetic variations, including 38 novel ones, were found and consisted of 4 in the 5'-flanking region, 21 (5 synonymous and 16 nonsynonymous) in the coding exons, and 30 in the introns. Nine novel nonsynonymous SNPs, 29C>A (Ala10Glu), 325T>A (Tyr109Asn), 451A>G (Asn151Asp), 733A>T (Ile245Phe), 793G>A (Glu265Lys), 1543G>A (Val515Ile), 1572T>G (Phe524Leu), 1666A>C (Ser556Arg), and 2678A>G (Asn893Ser), were found at allele frequencies between 0.15 and 0.88%. Two known nonsynonymous variations reported only in Japanese, 1003G>T (*11, Val335Leu) and 2303C>A (Thr768Lys), were found at allele frequencies of 0.15 and 2.8%, respectively. SNP and haplotype distributions in Japanese were quite different from those reported previously in Caucasians. This study provides fundamental information for pharmacogenetic studies for evaluating the efficacy and toxicity of 5-FU in Japanese and probably East Asians.
二氢嘧啶脱氢酶(DPD)是5-氟尿嘧啶(5-FU)的失活限速酶,其缺乏与发生5-FU严重或致命毒性的风险相关。在本研究中,为了寻找日本人中编码DPD的DPYD基因变异,对包括接受5-FU治疗的癌症患者在内的341名受试者的DPYD假定启动子区域、所有外显子及侧翼内含子进行了测序。共发现55个基因变异,其中38个为新变异,包括5'-侧翼区域4个、编码外显子21个(5个同义变异和16个非同义变异)以及内含子30个。发现9个新的非同义单核苷酸多态性(SNP),分别为29C>A(Ala10Glu)、325T>A(Tyr109Asn)、451A>G(Asn151Asp)、733A>T(Ile245Phe)、793G>A(Glu265Lys)、1543G>A(Val515Ile)、1572T>G(Phe524Leu)、1666A>C(Ser556Arg)和2678A>G(Asn893Ser),等位基因频率在0.15%至0.88%之间。还发现两个仅在日本人中报道过的已知非同义变异,分别为1003G>T(*11,Val335Leu)和2303C>A(Thr768Lys),等位基因频率分别为0.15%和2.8%。日本人的SNP和单倍型分布与先前报道的高加索人有很大差异。本研究为评估5-FU在日本人及可能的东亚人中的疗效和毒性的药物遗传学研究提供了基础信息。